Introduction: Propofol causes a profound inhibition of fatty acid oxidation (FAO) and reduces
Introduction
Propofol is a short-acting hypnotic agent, which is reportedly administered to 100 millions of patients each year and which was has been on the WHO list of most essential drugs for more than 10 years [1] . However, in last three decades, fatal complications of propofol administration were reported and defined as Propofol infusion syndrome (PRIS) [2, 3] . The syndrome typically includes metabolic acidosis, arrhythmias, ECG changes, hyperlipidaemia, fever, hepatomegaly, rhabdomyolysis, cardiac and/or renal failure. Risk of developing PRIS increases with higher dose and duration of infusion [4] , and several studies in animals [5] [6] [7] [8] [9] and humans [10] , [11] [12] [13] suggest that this syndrome might be an extreme manifestation in susceptible individuals of propofol inhibitory effect on fatty acid oxidation (FAO) and/or electron-transfer chain. Vanlander et al. in a study on rodents [14] first brought evidence for a hypothesis, that due to structural similarity of propofol and Coenzyme Q (CoQ), at least some effects of propofol on bioenergetics are caused by the inhibition of CoQ-dependent electron transfer pathways. Other mechanisms are possible, too, including metabolic rearrangement at translational level [15, 16] . It is unknown whether increased concentration of substrates can overcome propofolinduced inhibition, a feature that would point towards competition of propofol with the respective substrate, or whether the presence of propofol influences the maximum flux through the ETC, which would point towards inhibition outside the substrate-binding sites of the enzymes or an interruption of electron flux through the respiratory chain, such as at the level of CoQ.
The insight into the mechanisms of propofol toxicity was mostly obtained from experiments in animals and it is currently unknown whether effects of propofol can be reproduced in human tissues.
In this study, we assessed propofol-effect on energy metabolism in skeletal and heart muscle in humans and rats. We aimed to (1.) clarify the inter-species differences in the effect of propofol and (2.) elucidate the Michaelis-Menten characteristics of propofol-induced inhibition of metabolic pathways that will have been found to be inhibited by propofol. In order to maximise biological plausibility of our results, we performed our key experiments on tissue homogenates containing mitochondrial networks in cytosolic context [17] .
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Methods
Skeletal and heart muscle samples
Overall study design is shown in Fig 1. All experiments were performed ex vivo, with all the respirometry measurement being done on fresh tissue homogenates. Human skeletal muscle biopsies were obtained from m. vastus lateralis ( 300 mg) from metabolically healthy volunteers (n=11, 4 males, 7 females, aged 63±10 years) undergoing hip replacement surgery at Department of Orthopaedic Surgery in FNKV University Hospital in Prague. We excluded both patients receiving propofol anaesthesia during surgery and patients with history of mitochondrial disorder, diabetes mellitus or any other metabolic disease except treated stable hypothyroidism. Human heart muscle biopsies ( 100 mg) were taken from left ventricle myocardium from brain-dead donors (n=10) free of cardiac disease, whose hearts were not suitable for transplantation due to donor age over 50 years or due to logistical reasons, at the Transplant Centre of Institute of Clinical and Experimental Medicine in Prague, Czech Republic. All skeletal muscle donors gave a prospective written informed consent. In brain dead donors, organ retrieval consent process was performed in accordance with Czech legal and ethical requirements and the need for specific informed consent for this study was waived by Research Ethics Boards in both participating institutions, which also reviewed and approved the protocol of the study. Detailed characteristics of brain dead donor subjects are in Supplementary appendix Table S1 . 
Preparation of tissue homogenates
Muscle biopsy samples were put in pre-cooled biopsy preservation and relaxing medium (BIOPS) consisting of 2.77 mM CaK 2 EGTA, 7.23 mM K 2 EGTA, 5.77 mM Na 2 ATP, 6.56 mM MgCl 2 x 6 H 2 O, 20 mM taurine, 15 mM Na 2 Phosphocreatine, 20 mM imidazole, 0.5 mM dithiothreitol and 50 mM MES hydrate (pH adjusted to 7.1 at 4°C) [18] . Skeletal and heart muscle homogenates were prepared according to the protocols previously described by our research group 14,17 and in the stepby-step protocol in Supplementary Appendix. Briefly, in skeletal muscle samples, the connective and 5 adipose tissue was removed using scissors and forceps under microscope and muscle sample was gently blotted by sterile cotton gauze, weighted on the analytical scale and cut into fine fragments.
Tissue fragments were then placed into the glass grinder of 2 mL Potter-Elvehjam homogenizer set (Wheaton TM , Millville, USA) and diluted in the respiration medium (K medium) containing 80 mM KCl, 10 mM Tris HCl, 5mM KH 2 PO 4 , 3 mM MgCL 2 , 1 mM EDTA, 0.5 mg/mL BSA (pH adjusted to 7.4 at 24 °C) to obtain 10 and 2.5 % tissue solution ( 100 mg of human and 25 mg of rat skeletal muscle tissue /per 1 mL of K medium, respectively). Tissue fragments were then homogenized by 5-6 slow strokes up and down with 2 mL Potter-Elvehjam teflon/glass homogenizer (clearance 0.25 mm; Wheaton TM , Millville, USA) driven by electric motor homogenizer (750 rpmi; HEi-Torque Value 100, Heidolph, Germany) [17] . Heart muscle homogenates were prepared similarly [19] . After removal of connective tissue and fat, fresh myocardium was dissected into fine fragments and 2. 
High resolution respirometry
All functional studies were performed using high resolution respirometry Oxygraph-2k (O2k; Oroboros Instruments, Innsbruck, Austria). The method is based on monitoring oxygen concentration with a polarographic oxygen electrode in two closed chambers allowing for 2 parallel measurements.
Oxygen flux is calculated as the negative derivative of oxygen concentration [20, 21] which is continually measured during sequential addition of substrates, uncouplers or inhibitors. In our experiments, we performed all initial steps including washing the chamber and calibration of O2k according to the manufacturer's recommendations [22] . Oxygen solubility factor was set up to 0. 
Reagents preparation
All reagents were purchased from Sigma-Aldrich (St. Louis, USA). Substrates were dissolved in distilled water (pH adjusted to 7.0). Uncouplers and inhibitors were dissolved in DMSO. Propofol (2,6-diisopropyplhenol) stock (10 mg/mL) was prepared fresh before each measurement by dilution in 10 % ethanol.
Substrate-uncoupler-inhibitor-titration (SUIT) protocols for dose-finding studies
In the dose-finding studies, we tested a range of propofol concentrations, from those resembling propofol levels in human plasma during anaesthesia and sedation (2.5; 5 and 10 µg/mL) [23, 24] to supra-physiological concentrations used in previous animal studies (25; 50 and 100 µg/mL) [5] [6] [7] 25] . Propofol or the respective concentration of control vehicle (ethanol) were injected directly into the chamber and both measurements were performed simultaneously.
Global mitochondrial functional indices. In the first two experiments, we assessed propofol influence on global bioenergetic parameters. Inhibition of electron transfer chain (ETC).
Firstly, we used a sequential addition of 2.5 mM malate (mal) plus 15 mM glutamate (glut), 1 mM ADP, 10 µM cytochrome c, 10 mM succinate (suc), 1 µM oligomycin, 0.8 and 1.5 µM FCCP (for skeletal muscle and heart muscle homogenates, resp.) followed by final injection of increasing concentrations of either propofol or vehicle. This protocol allowed us to assess possible propofol-induced inhibition of ETC in ADP-stimulated respiration. Uncoupling of inner mitochondrial membrane (Leak). Secondly, we looked at possible uncoupling of inner mitochondrial membrane and changed the protocol as follows: addition of 2.5 mM malate plus 15 mM glutamate, 1 mM ADP, 10 µM cytochrome c, 10 mM succinate and 1 µM oligomycin was followed by final titration of propofol concentrations to induce feasible uncoupling (Fig. 2) . 
Fatty acid oxidation (FAO).
Initially, 2.5 mM malate was used as a sparkler followed by 1 mM ADP. Respiration was then stimulated by addition of 25 µM of palmitoyl-carnitine (heated to 70°C).
Lastly, propofol was added in a step-wise manned to observe its potential influence on FAO.
Kinetic characteristics experiments.
Because we found propofol to inhibit CI-driven respiration and FAO in concentrations that are clinically relevant, for these pathways we performed substrate titrations in parallel in control chamber and in the presence of a fixed concentration of propofol (10 µg/ml in rodents and 2. 
Spectrophotometric analyses of isolated respiratory complexes
In order to assess effects of propofol on isolated complexes I, II, III and IV, we used classical spectrophotometric method on frozen homogenates as described by Spinazzi et al [26] . We performed parallel assays of samples containing 10 µg/ml of propofol, the solvent (ethanol 0.5 %) and fresh media. 
Statistics
Data from dose-finding were processed using linear mixed effect model (LMEM). In the fixed part, the model consists of a dependent continuous parameter (e.g. oxygen flux) and a categorical independent parameter (e.g. propofol concentration, species human vs rodent). In the random part, there was a random intercept (ID of a patient) and correlation matrix of residuals, if statistically 
Results
Effect of propofol on bioenergetics in cytosolic context. Propofol inhibited in a concentration-
dependent manner oxygen fluxes driven by substrates for CI and by palmitoyl-carnitine, and to lesser extent of oxygen fluxes driven by substrate for Complex II (Fig. 3) . In turn, respiratory chain capacity (RCC) was reduced by propofol, too. Skeletal muscle (both of man and rat) seemed to be more sensitive to inhibition of CI-driven respiration by propofol than myocardium. In contrast, CII-driven respiration, FAO and RCC were first inhibited in human myocardium during propofol titration. The inhibition of FAO and CI-driven respiration were inhibited at concentrations of propofol seen in plasma of anaesthetized patients, i.e. 2.5 and 10 µg/ml and human tissues seemed to be more sensitive than rodents'.
Apparently, there was no significant effect of propofol on Complex IV-driven respiration or on the leak of electrons through inner mitochondrial membrane. In light of this we selected CI-driven and palmitoyl carnitine-driven respirations for kinetic studies, in which we use 10 µg/ml (for human tissues 2.5 and 10 µg/ml, respectively) of propofol. Figures 2   and 4) . Propofol influenced kinetic parameters of Complex I-driven respiration in human, but not rat muscle tissues: it reduced Vmax and to a lesser, but still significant extend, the Km. At 2.5 µg/ml, only Vmax in human skeletal muscle was significantly affected (Fig. 4A,B) . With regards to FAO, even the lower concentration (2.5 µg/ml) of propofol significantly reduced both Km and Vmax in both human skeletal muscle and heart tissues. The higher concentration (10 µg/ml) also tended to reduce Vmax in rat tissues, but the reduction was only significant in skeletal muscle (Fig. 4 C,D) .
Effects of propofol on isolated complexes. Of note there was no significant inhibition by 10 µg/ml of propofol of any of the complexes if measured in isolation by spectrophotometry (See Supplementary Appendix, Fig. S1 ). 
Discussion
To our knowledge this is the first study that investigates the effects of clinically relevant concentration of propofol on cellular bioenergetics in human skeletal and heart muscles obtained from volunteers and brain-dead organ donors. The main finding of our study is that human skeletal and cardiac muscle tissues are more sensitive to bioenergetic effects of propofol when directly compared to rodent samples. Palmitoyl-carnitine driven respiration (FAO) is particularly more sensitive to low concentrations of propofol in humans compared to rat (Fig. 3E ). In addition, we have found that in the model of short-term exposure to propofol, there is a different pattern of inhibition in Complex I-driven respiration from palmitoyl carnitine-driven respiration. In our experiments, we measured the rate of those that are able to influence overall capacity of ETC (see Fig 3A, 3B) . Km long remains unaffected and only a reduction of Vmax is seen (see Fig. 4B ), in keeping with a non-competitive nature of the inhibition. Because the activity of isolated complexes was unaffected by the same concentration of propofol (10 µg/ml), inhibition of Complex I-driven respiration could be explained by propofol reducing electron flux outside binding sites of the enzymes, such as reducing downstream flow of electrons by interfering with Coenzyme Q. On the contrary, palmitoyl carnitine-driven respiration was affected differently by propofol: both Vmax and Km were reduced ( Fig. 4C and 4D ) suggesting a pattern of mixed or uncompetitive inhibition. Because FAO was inhibited even by concentrations <5 µg/ml (Fig. 3E) which are not high enough to cause any measurable reduction of ETC capacity (Fig 3A) or Complex II substrate-driven respiration (Fig. 3D) , the reduction of downstream flux of electrons by propofol can be effectively ruled out as the only cause of FAO inhibition. Propofol has long been thought to inhibit carnitine-palmitoyl transferase I (CPT-1) after Wolf [11] reported in the blood of a child with PRIS a significant elevation of acyl-CoA including malonyl-CoA, the main physiological inhibitor of CAP-1 and in turn the main regulator of fatty acids transport into the mitochondrial matrix. Of note, CAP-1 converts acyl-CoA to acyl-carnitine and in this experiment, we used palmitoyl-carnitine as the substrate. In turn, the observed inhibition of FAO cannot be explained by effects of propofol on CPT-1 as often reported [27, 28] . According to our data, the inhibition of FAO by propofol in human skeletal and cardiac muscle cell must occur between CPT-2 and entry of electrons from FAO into ETC via Complex II, and not at the level of CPT-1.
Our results complement the finding of Branca et. al. [5] and Rigoulet et al. [25] who found inhibition of ETC capacity in isolated rat liver, mostly due to inhibition of Complex I. In keeping with our results, rat heart mitochondria were found to be more resistant to the inhibitory effects of propofol as the effects of propofol were only seen with concentrations > 55 µg/ml (>300 µmol/l) [6] .
Rare in vivo studies in guinea pigs [29] or rat [14] demonstrated -in line with our results -the inhibitory effect of propofol in ranges of 9-36 µg/ml (50-200 µmol/l) [29] or >4.5 µg/ml (>25 µmol/l)[14], respectively, whilst isolated respiratory complexes were also unaffected by the same concentration of propofol [14] . Vanlender et al. was also able to mitigate propofol toxicity by adding Coenzyme Q to tissue homogenate[14] -a result we were unable to reproduce neither with Coenzyme Q nor with its analogue idebenone, mainly due to the toxicity of its solvent dimethylsulfoxide (data not shown). Yet, the kinetic characteristics of inhibition of Complex I-driven respiration in human tissues observed in this study, is in keeping with Coenzyme Q hypothesis.
The major strength of our work is that we directly measured the effects of propofol on human tissues that are clinically affected by PRIS, such as skeletal muscle (rhabdomyolysis) or myocardium (heart failure, arrhythmias). Native human hearts are very difficult to obtain and we used hearts retrieved from brain-dead organ donors to preform our experiments. We experimented with concentrations of propofol that are found in blood of patients sedated or anaesthetized with propofol (2-11 µg/ml) [24] and used biologically plausible bioenergetic model of mitochondria in their cytosolic context [17] . The finding of the differences between human and rodent tissues exposed to propofol we consider very important for the interpretation of the experiments in animal models of PRIS [5, 7, 14, 26, 29, 30] . On the other hand, the use of muscle homogenates only allows short term experimental exposure [17] , which may not allow sufficient time for incorporation of propofol into the inner mitochondrial membrane [14] or affect gene expression [15, 16] . Also, measuring parameters from the classic enzyme kinetics (such as Vmax or Km) may not be fully appropriate in systems that are likely multicompartmental and complex, such as bioenergetic pathways in mitochondria.
In conclusion, we demonstrated for the first time in fresh human skeletal muscle and cardiac tissue homogenates the inhibition by propofol of electron transfer chain and fatty acid oxidation. We have shown that human tissues are more sensitive to propofol than rat and that fatty acid oxidation in humans is very sensitive to an inhibition by propofol and occurs at much lower concentrations, before any observable reduction of electron flux through ETC. Kinetic characteristics of fatty acid oxidation suggest a different mechanism of inhibition from previously proposed CTP-1 inhibition. Noncompetitive nature of the inhibition of Complex I substrate-driven respiration is consistent with the hypothesis that propofol effect on mitochondria are mediated by its interference with Coenzyme Q.
